Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by duskwon Jul 23, 2012 1:39pm
166 Views
Post# 20142953

RE: RE: Q2 CC

RE: RE: Q2 CC

"Yet here we are with a very low share price and the main reason is poor communications to the street."

I disagree - the main reason is simply, profitability. Expenses are way too high for the revenue. Management keeps thinking and saying revenues will increase to cover the expenses - after demonstrating for 3 years this isn't happening, it's time to re-think the business. CUT EXPENSES - CUT R&D - CUT MARKETTING --> make the company profitable. Revenue growth might slow due to decreased R&D spending but will provide some shareholder value. If the shareprice appreciates after that perhaps it can be leveraged into some growth.

Take a look at the cumulative R&D spending from 2008-2012. It's ridiculous how much money has been spent on development without significant revenue growth or profitability.

Even a modest reduction in R&D expenses by 15-20% will have a significant impact on the bottom line. 

In 2011 the company spent $11.5 million in R&D, and $14 million in S&M. Reducing R&D by 20% would have added $2.3 million to the bottom line. Reducing S&M by 10% would have added an additional $1.4 million... for a total of $3.7 million.

 

 

Bullboard Posts